Table 1 Baseline characteristics.

From: Study on the relationship between in-stent neoatherosclerosis and chronic kidney disease: an optical coherence tomography study

 

Total

(n = 220)

eGFR ≥ 90

(G1, n = 80)

60 ≤ eGFR<90

(G2, n = 86)

eGFR<60

(G3, n = 54)*

p Value

p Value

G1 vs. G2

p Value

G1 vs. G3

p Value

G2 vs. G3

Age, M ± SD, years

63.45± 10.39

58.40 ± 9.06

63.50 ± 9.85

70.87 ± 8.59

0.000

0.000

0.000

0.000

Gender

    

0.006

0.001

0.399

0.33

Male, n(%)

177(80.5%)

57(71.3%)

78(90.7%)

42(77.8%)

    

Female, n(%)

43(19.5%)

23(28.8%)

8(9.3%)

12(22.2%)

    

The incidence type of this time

    

0.952

   

ACS, n(%)

 

36(37.5%)

37(38.5%)

23(24.0%)

    

CCS, n(%)

 

44(35.5%)

49(39.5%)

31(25.0%)

    

Previous MI, n (%)

54(24.5%)

19(23.8%)

23(26.7%)

12(22.2%)

0.815

   

Smoker, n(%)

103(46.8%)

37(46.3%)

44(51.2%)

22(40.7%)

0.481

   

Hypertension, n(%)

135(61.4%)

42(52.5%)

49(57.0%)

44(81.5%)

0.002

0.563

0.001

0.003

Diabetes, n(%)

59(26.8%)

22(27.5%)

19(22.1%)

18(33.3%)

0.339

   

Hyperlipidemia, n(%)

60(27.3%)

22(27.5%)

27(31.4%)

11(20.4%)

0.361

   

Laboratory findings

        

White blood cells, M(IQR), ×109/L

7.06(5.76, 8.68)

7.23(5.76, 8.93)

6.98(5.52, 8.21)

6.99(6.01, 8.44)

0.752

   

Hemoglobin, M ± SD, g/L

140.25± 18.17

140.90 ± 18.77

144.14 ± 15.61

133.09 ± 19.27

0.002

0.241

0.013

0.000

Platelet, M ± SD, ×109/L

204.78± 72.88

216.20 ± 68.37

198.06 ± 80.77

198.57 ± 64.85

0.214

   

Total cholesterol,

M ± SD, mmol/L

4.09± 1.47

4.06 ± 1.37

4.05 ± 1.66

4.20 ± 1.30

0.813

   

Triglycerides, M(IQR), mmol/L

1.53(1.16, 2.40)

1.64(1.17, 2.38)

1.51(1.13, 2.56)

1.46(1.18, 2.15)

0.975

   

HDL-C, M ± SD, mmol/L

1.09± 0.31

1.08 ± 0.28

1.11 ± 0.36

1.09 ± 0.24

0.725

   

LDL-C, M ± SD, mmol/L

2.37± 0.94

2.38 ± 0.88

2.31 ± 1.03

2.45 ± 0.91

0.681

   

ALT, M(IQR), U/L

26.00(18.00, 36.00)

27.00(19.25, 39.00)

27.00(19.00, 36.00)

20.50(15.00, 32.25)

0.024

0.609

0.012

0.021

TBIL, M(IQR), U/L

12.45(9.33, 17.00)

12.40(8.23, 17.50)

14.25(10.38, 17.88)

11.35(8.20, 13.53)

0.017

0.214

0.144

0.003

Troponin T, M(IQR), ng/L

3.00(1.00, 6.00)

12.36(6.81, 74.66)

12.56(8.74, 23.84)

21.68(12.50, 58.41)

0.003

0.859

0.010

0.001

NTPro-BNP, M(IQR), pg/ml

212.85(92.76, 673.03)

180.55(86.94, 586.68)

193.75(78.46, 415.18)

476.60(120.50, 1735.50)

0.004

0.627

0.005

0.002

Medicine use

        

Aspirin, n(%)

207(94.1%)

77(96.3%)

80(93.0%)

50(92.6%)

0.622

   

Clopidogrel, n(%)

197(89.5%)

72(90.0%)

78(90.7%)

47(87%)

0.778

   

Statin, n(%)

194(88.2%)

73(91.3%)

75(87.2%)

46(85.2%)

0.531

   
  1. *Including 3 hemodialysis patients.
  2. eGFR: estimated glomerular filtration rate; ACS: acute coronary syndrome; CCS: chronic coronary syndrome; MI: myocardial infarct; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ALT: Alanine Transaminase; TBIL: total bilirubin; NTPro-BNP: N-terminal pro-B-type natriuretic peptide; M(SD) = mean(stand deviation); M(IQR) = median(interquartile range); p Value<0.05 or the Bonferroni correction for two group comparison was a new significance level of 0.05/3 = 0.017.
Back to article page